FDA Approved: DALIRESP — Original Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved the original application for Daliresp (roflumilast), a PDE-4 inhibitor, to reduce the risk of COPD exacerbations in patients with severe chronic ob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daliresp (roflumilast)

Snippet

ORIG AP for DALIRESP (ROFLUMILAST)